PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
← catalyst calendarNCT06157151 · readout in 84 d
Sponsored by Precigen, Inc (industry) · PGEN — their whole pipeline →. With National Cancer Institute (NCI).
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
24estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-11 | actual | When the study began enrolling |
| Primary completion | 2026-11-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cervical Cancer
- HPV-Related Carcinoma
- HPV-Related Malignancy
- Recurrent Cervical Carcinoma
- Metastatic Cervical Cancer
Intervention
- Biological: PRGN-2009 plus Pembrolizumab
Primary outcome
what the primary-completion date above is the date OFDetermine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
measured 1 year
Permalink · PGEN's whole pipeline · Catalyst calendar · Every registered study · What changed